Clinical glycoproteomics: methods and diseases DOI Creative Commons
Yujia Wang,

Kaixin Lei,

Lijun Zhao

et al.

MedComm, Journal Year: 2024, Volume and Issue: 5(10)

Published: Oct. 1, 2024

Abstract Glycoproteins, representing a significant proportion of posttranslational products, play pivotal roles in various biological processes, such as signal transduction and immune response. Abnormal glycosylation may lead to structural functional changes glycoprotein, which is closely related the occurrence development diseases. Consequently, exploring protein can shed light on mechanisms behind disease manifestation pave way for innovative diagnostic therapeutic strategies. Nonetheless, study clinical glycoproteomics fraught with challenges due low abundance intricate structures glycosylation. Recent advancements mass spectrometry‐based have improved our ability identify abnormal glycoproteins samples. In this review, we aim provide comprehensive overview foundational principles recent glycoproteomic methodologies applications. Furthermore, discussed typical characteristics, underlying functions, diseases, brain cardiovascular cancers, kidney metabolic Additionally, highlighted potential avenues future glycoproteomics. These insights provided review will enhance comprehension methods diseases promote elucidation pathogenesis discovery novel biomarkers targets.

Language: Английский

AXL in cancer: a modulator of drug resistance and therapeutic target DOI Creative Commons

Yaoxiang Tang,

Hongjing Zang, Qiuyuan Wen

et al.

Journal of Experimental & Clinical Cancer Research, Journal Year: 2023, Volume and Issue: 42(1)

Published: June 16, 2023

Abstract AXL is a member of the TAM (TYRO3, AXL, and MERTK) receptor tyrosine kinases family (RTKs), its abnormal expression has been linked to clinicopathological features poor prognosis cancer patients. There mounting evidence supporting AXL's role in occurrence progression cancer, as well drug resistance treatment tolerance. Recent studies revealed that reducing can weaken cells' resistance, indicating may be promising target for anti-cancer treatment. This review aims summarize structure, mechanisms regulating activating it, pattern, especially drug-resistant cancers. Additionally, we will discuss diverse functions mediating potential inhibitors

Language: Английский

Citations

47
Fighting drug-resistant lung cancer by induction of NAD(P)H:quinone oxidoreductase 1 (NQO1)-mediated ferroptosis DOI
Jie Yu, Bingling Zhong, Lin Zhao

et al.

Drug Resistance Updates, Journal Year: 2023, Volume and Issue: 70, P. 100977 - 100977

Published: June 1, 2023

Language: Английский

Citations

46
The utilization and advancement of quartz crystal Microbalance (QCM): A mini review DOI
Luyu Wang, Jia Song, Chunyang Yu

et al.

Microchemical Journal, Journal Year: 2024, Volume and Issue: 199, P. 109967 - 109967

Published: Jan. 16, 2024

Language: Английский

Citations

20
EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47 DOI

Liyang Hu,

Weitao Zhuang,

Mao-jian Chen

et al.

Journal of Thoracic Oncology, Journal Year: 2024, Volume and Issue: 19(8), P. 1186 - 1200

Published: March 27, 2024

Language: Английский

Citations

17
AXL signaling in cancer: from molecular insights to targeted therapies DOI Creative Commons
Monika Yadav, Anuj K. Sharma, Ketki Patne

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2025, Volume and Issue: 10(1)

Published: Feb. 9, 2025

Abstract AXL, a member of the TAM receptor family, has emerged as potential target for advanced-stage human malignancies. It is frequently overexpressed in different cancers and plays significant role various tumor-promoting pathways, including cancer cell proliferation, invasion, metastasis, epithelial–mesenchymal transition (EMT), angiogenesis, stemness, DNA damage response, acquired therapeutic resistance, immunosuppression, inflammatory responses. Beyond oncology, AXL also facilitates viral infections, SARS-CoV-2 Zika highlighting its importance both virology. In preclinical models, small-molecule kinase inhibitors targeting have shown promising anti-tumorigenic potential. This review primarily focuses on induction, regulation biological functions mediating these pathways. We discuss range strategies, recently developed tyrosine (TKIs), monoclonal antibodies, antibody–drug conjugates (ADCs), anti-AXL-CAR, combination therapies. These interventions are being examined clinical studies, offering improved drug sensitivity efficacy. further mechanisms particularly crosstalk between other critical kinases (RTKs) such c-MET, EGFR, HER2/HER3, VEGFR, PDGFR, FLT3. Finally, we highlight key research areas that require exploration to enhance AXL-mediated approaches outcomes.

Language: Английский

Citations

3
Protein degradation: expanding the toolbox to restrain cancer drug resistance DOI Creative Commons
Hui Ming, Bowen Li, Jingwen Jiang

et al.

Journal of Hematology & Oncology, Journal Year: 2023, Volume and Issue: 16(1)

Published: Jan. 24, 2023

Abstract Despite significant progress in clinical management, drug resistance remains a major obstacle. Recent research based on protein degradation to restrain has attracted wide attention, and several therapeutic strategies such as inhibition of proteasome with bortezomib proteolysis-targeting chimeric have been developed. Compared intervention at the transcriptional level, targeting process seems be more rapid direct strategy. Proteasomal proteolysis lysosomal are most critical quality control systems responsible for proteins or organelles. Although proteasomal inhibitors (e.g., chloroquine) achieved certain improvements some application scenarios, their routine practice is still long way off, which due lack precise capabilities inevitable side effects. In-depth studies regulatory mechanism regulators, including E3 ubiquitin ligases, deubiquitylating enzymes (DUBs), chaperones, expected provide clues developing reducing Here, we discuss underlying mechanisms regulating efflux, metabolism, DNA repair, target alteration, downstream bypass signaling, sustaining stemness, tumor microenvironment remodeling delineate functional roles resistance. We also highlight specific DUBs, discussing possible modulating cancer A systematic summary molecular basis by regulates will help facilitate development appropriate strategies.

Language: Английский

Citations

30
Opportunities and Challenges for Inhalable Nanomedicine Formulations in Respiratory Diseases: A Review DOI Creative Commons

Xujun Feng,

Yuan Shi, Ye Zhang

et al.

International Journal of Nanomedicine, Journal Year: 2024, Volume and Issue: Volume 19, P. 1509 - 1538

Published: Feb. 1, 2024

Abstract: Lungs experience frequent interactions with the external environment and have an abundant supply of blood; therefore, they are susceptible to invasion by pathogenic microorganisms tumor cells. However, limited pharmacokinetics conventional drugs in lungs poses a clinical challenge. The emergence different nano-formulations has been facilitated advancements nanotechnology. Inhaled nanomedicines exhibit better targeting prolonged therapeutic effects. Although great potential, still present several unknown risks. Herein, we review (1) physiological anatomy their biological barriers, (2) toxicology nanomaterial formulations lungs; (3) current nanomaterials that can be applied respiratory system related design strategies, (4) applications inhaled treating disorders, vaccine design, imaging detection based on characteristics nanomaterials. Finally, (5) analyze summarize challenges prospects for disease applications. We believe nanomaterials, particularly nano-formulations, excellent application diseases. emphasize simultaneous toxic side effects must considered during these emerging medicines. This study aims offer comprehensive guidelines valuable insights conducting research domain system. Keywords: nanoparticles, system, lungs, nanotechnology

Language: Английский

Citations

11
Modulation of almonertinib resistance in non-small cell lung cancer by cancer-associated fibroblasts through HK2-mediated glycolysis and SKP2 signaling DOI Creative Commons

Guohao Wei,

Lingyao Fan,

Xiaoyan Song

et al.

Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)

Published: Feb. 15, 2025

Almonertinib is a third-generation EGFR-TKI, and studies on its resistance mechanisms are lacking. Cancer-associated fibroblasts (CAFs) can influence to targeted therapeutics, but their role mechanism of action in relation almonertinib unclear. The study explored relationships among glycolysis, cancer-associated (CAFs), resistance. A dose-escalation method was used develop the almonertinib-resistant cell line H1975AR. Hexokinase 2 (HK2) effects were evaluated using Cell Counting Kit-8 assays, transcriptome sequencing, western blotting, real-time PCR, siRNA glucose consumption, lactate production assays. Differential gene expression analysis assays H1975 cells cultured with CAF-conditioned medium (H1975/CAF-CM) revealed S-phase kinase-associated protein (SKP2) as target driving HK2. impact HK2 inhibitors H1975/CAF-CM assessed colony formation, wound healing, transwell, flow cytometry apoptosis H1975AR displayed elevated glycolysis Subsequently, we showed that knockdown reduced cells. induced upregulation HK2, which reversed by SKP2. CAFs regulate HK2-mediated through SKP2, promoting NSCLC. promotes

Language: Английский

Citations

1
Metal-organic coordinated self-assembled nanomedicine for enhanced cuproptosis-mediated chemo-photo-chemodynamic synergistic therapy of non-small cell lung cancer DOI
R.P. Liu,

Ruirui Zhao,

Zi-Wei Yu

et al.

Chemical Engineering Journal, Journal Year: 2025, Volume and Issue: unknown, P. 161305 - 161305

Published: March 1, 2025

Language: Английский

Citations

1
Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use? DOI Open Access
Michael J. Duffy, Minhong Tang, Subhasree Rajaram

et al.

Cancers, Journal Year: 2022, Volume and Issue: 14(18), P. 4499 - 4499

Published: Sept. 16, 2022

Mutant p53 is one of the most attractive targets for new anti-cancer drugs. Although traditionally regarded as difficult to drug, several strategies have recently become available targeting mutant protein. One promising these involves use low molecular weight compounds that promote refolding and reactivation its wild-type form. Several such reactivating drugs are currently undergoing evaluation in clinical trials, including eprenetapopt (APR-246), COTI-2, arsenic trioxide PC14586. Of these, clinically advanced which has completed phase I, II III latter patients with TP53 myelodysplastic syndrome. no data on efficacy eprenetapopt, preliminary results suggest drug relatively well tolerated. Other progressed trials involve promoting degradation protein exploiting development vaccines. With all ongoing we should soon know if can be used cancer treatment. If any show efficacy, it may a transformative treatment since so prevalent this disease.

Language: Английский

Citations

34